The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
Th...
This report highlights the issues surrounding high prices and poor supply of the drugs needed to treat drug-resistant tuberculosis (DR-TB). The report provides an overview of available drug-resistant TB medicines, including drug sources, quality status, and price.
This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.
This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to...
This new report on anti-tuberculosis (TB) drug resistance by the World Health Organization (WHO) updates “Anti-tuberculosis drug resistance in the world: Report No. 4” published by WHO in 2008. It summarizes the latest data and provides latest estimates of the global epidemic of multidrug and...
This report discusses the WHO/TDR sponsored evaluation of 19 commercially available rapid diagnostic tests for tuberculosis. The evaluation assessed diagnostic test performance, reproducibility, and operational characteristics.
This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to...
This report on the uses of nucleic acid amplification (NAA) tests for diagnosis of TB is based on contributions of an expert panel of consultants convened by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL). The report presents the...
This report from the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) describes its activities for the year 2008. It provides its history, mission, and key priorities, which are reducing health disparities, encouraging program collaboration and service integration, and...
This white paper outlines NCHHSTP’s strategic vision for program collaboration and service integration, building on and refining concepts.